For the year ending 2025-12-31, ESPR made $403,135K in revenue. -$22,682K in net income. Net profit margin of -5.63%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 403,135 | 332,314 | ||
| Cost of goods sold | 129,224 | - | ||
| Research and development | 47,852 | 46,238 | ||
| Cost of goods sold | - | 68,601 | ||
| Selling, general and administrative | 165,786 | 163,073 | ||
| Total operating expenses | 342,862 | 277,912 | ||
| Income (loss) from operations | 60,273 | 54,402 | ||
| Interest expense | 84,604 | 59,251 | ||
| Loss on extinguishment of debt and exchange transaction | 0 | -54,918 | ||
| Other income, net | 3,490 | 8,022 | ||
| Loss before income taxes | -20,841 | - | ||
| Provision for taxes on income | 1,841 | - | ||
| Net loss | -22,682 | -51,745 | ||
| Unrealized gain on investments | 0 | - | ||
| Total comprehensive loss | -22,682 | -51,745 | ||
| Basic EPS | -0.11 | -0.28 | ||
| Diluted EPS | -0.11 | -0.28 | ||
| Basic Average Shares | 207,865,080 | 187,181,856 | ||
| Diluted Average Shares | 207,865,080 | 187,181,856 | ||
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)